一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.3800 | -0.2000 | -90 | -0.6400 | | 每股净资产（元） | 1.96 | 2.34 | -16.24 | 2.54 | | 每股公积金(元) | 1.29 | 1.29 | 0 | 1.29 | | 每股未分配利润(元) | -0.49 | -0.11 | -345.45 | 0.10 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 5.81 | 6.45 | -9.92 | 7.11 | | 净利润(亿元) | -1.18 | -0.63 | -87.3 | -1.98 | | 净资产收益率(%) | -17.73 | -8.39 | -111.32 | -22.19 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 6779.14万股，累计占流通股比： ...

阳普医疗科技股份有限公司 独立董事 2024 年度述职报告 （李璐） 各位股东及股东代表： 2024 年度，本人作为阳普医疗科技股份有限公司（以下简称"公司"）的 独立董事，严格按照《公司法》《证券法》等法律法规及《公司章程》《独立董 事工作制度》《独立董事专门会议工作制度》等公司制度的规定，诚实、勤勉、 独立地履行职责，发挥了独立董事作用。现将 2024 年度任职期间本人履行职责 的情况汇报如下： 一、独立董事的基本情况 李璐女士，1979 年生，博士学位，拥有丰富的审计经验，为中国注册会计 师（CPA）、英国特许公认注册会计师（ACCA）并拥有法律职业资格（2002 年首 届），2013 年入选湖北省首届会计领军人才，2019 年作为省唯一高校成员入选 财政部"国际化高端会计人才"培养工程。财政部中国注册会计师协会访问研究 员、技术专家，国家社科基金成果评审专家，湖北省社科专家库成员。现为中南 财经政法大学会计学院教授、博士生导师，中南财经政法大学支部主委，本公司 独立董事，兼任民革湖北省委会委员，湖北省民革经济专业委员会副主任委员， 湖北省审计学会副秘书长（2021 年连任），湖北省税务局特约监察员，武 ...

阳普医疗科技股份有限公司 独立董事 2024 年度述职报告 （白华） 各位股东及股东代表： 本人认为公司董事会的召集召开符合法定程序，重大经营事项均履行了相关 审批程序，合法有效。2024 年任职期间，本人对提交至各次董事会会议的各项 议案均投了赞成票，无提出异议的事项，也没有反对、弃权的情形。 （二）出席董事会专门委员会、独立董事专门会议情况 1.出席专门委员会会议情况 本人作为公司第六届董事会战略委员会、审计委员会、薪酬与考核委员会的 委员，在 2024 年任职期间主要履行了以下职责： （1）战略委员会 2024 年度，本人作为阳普医疗科技股份有限公司（以下简称"公司"）的 独立董事，严格按照《公司法》《证券法》等法律法规及《公司章程》《独立董 事工作制度》《独立董事专门会议工作制度》等公司制度的规定，诚实、勤勉、 独立地履行职责，充分发挥了独立董事作用。一方面，严格审核公司提交董事会 审议的相关议案，维护公司和各位股东，特别是中小股东的合法权益，促进公司 依法经营、规范运作；另一方面充分发挥本人的财会专业特长，为公司的审计、 内控、薪酬激励、战略规划等工作提出了相关意见和建议。现将 2024 年度本人 ...

董事会关于独立董事独立性情况的专项意见 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 阳普医疗科技股份有限公司（以下简称"公司"）董事会根据《上市公司独 立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等要求，并结合公司独立董事出具的《独立董事独立性自查情 况表》，董事会就公司独立董事（含 2024 年内离任的独立董事）的独立性情况 进行评估并作出以下专项意见： 证券代码：300030 证券简称：阳普医疗 公告编号：2025-018 阳普医疗科技股份有限公司 2024 年度，公司任职的独立董事白华、刘瑛、李璐、刘焕亮（因个人原因 辞职离任）均能够胜任独立董事的职责要求，其未在公司担任除独立董事以外的 任何职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不 存在妨碍进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等法律、法规、规范性文件及《公司章程》中关于独 立董事的任职资格及独立性 ...

阳普医疗科技股份有限公司 独立董事 2024 年度述职报告 （刘瑛） 各位股东及股东代表： 2024 年度，本人作为阳普医疗科技股份有限公司（以下简称"公司"）的 独立董事，严格按照《公司法》《证券法》等法律法规及《公司章程》《独立董 事工作制度》《独立董事专门会议工作制度》等公司制度的规定，诚实、勤勉、 独立地履行职责，充分发挥了独立董事作用。一方面，严格审核公司提交董事会 审议的相关议案，维护公司和各位股东，特别是中小股东的合法权益，促进公司 依法经营、规范运作；另一方面充分发挥本人的法律专业优势，为公司的审计工 作及内控、薪酬激励、战略规划等工作提出了相关意见和建议。现将 2024 年度 本人履行职责的情况汇报如下： 一、独立董事的基本情况 刘瑛女士，1978 年生，复旦大学研究生学历，法学博士，长期从事国际商 法、国际贸易法、国际金融法和中国涉外法的教学和研究。现任中山大学法学院 教授、博士生导师，中山大学涉外法治研究院副院长、本公司独立董事。同时担 任上海、武汉、珠海等地仲裁机构的仲裁员职务，以及在明阳智慧能源集团股份 公司任独立董事职务。 本人未在公司担任除独立董事以外的任何职务，也未在公司主要股 ...

舆情管理制度 第一章 总 则 第一条 为提高阳普医疗科技股份有限公司（以下简称"公司"）应对各类 舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股 价、商业信誉及正常生产经营活动造成的影响，切实保护公司及利益相关方尤其 是投资者的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》 《深圳证券交易所创业板股票上市规则》等相关法律法规和规范性文件及《阳普 医疗科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定，结合 公司实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成较大影响的传言或信息； （三）可能或已经影响社会公众投资者投资取向，造成股价异常波动的信息； 阳普医疗科技股份有限公司 （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第三条 本制度适用于公司及合并报表范围内的各子公司。 第二章 舆情管理的组织体系及其工作职责 第四条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。 第五条 公司成立应对舆情管理工作领导小组（以下 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 115.54 million, a decrease of 18.15% compared to CNY 141.15 million in the same period last year[5] - Net profit attributable to shareholders was CNY 7.81 million, an increase of 344.71% from a loss of CNY 3.19 million in the previous year[5] - The total profit for the period was CNY 8.79 million, a turnaround from a loss of CNY 1.62 million in the previous year, representing a 643.68% increase[11] - The net profit attributable to the parent company increased to ¥7,808,976.00, a growth of 345.79% compared to the previous year[12] - Total comprehensive income reached ¥7,855,506.07, reflecting an increase of 373.34% due to higher investment income from Shenzhen Yanghe[12] - Net profit for the period was ¥7,854,947.83, compared to a net loss of ¥2,887,667.65 in the previous period, indicating a significant turnaround[30] Cash Flow - The net cash flow from operating activities was CNY 13.60 million, down 15.02% from CNY 16.00 million in the same period last year[5] - Cash received from operating activities rose by 50.57% to ¥2,589,578.91, attributed to an increase in operational funds[12] - Cash flow from operating activities generated ¥13,597,008.76, down from ¥16,000,253.94 in the prior year, reflecting a decrease of approximately 15.0%[32] - The net cash flow from financing activities decreased significantly by 1638.76% to -¥102,345,843.10, as the company used its own funds to repay bank loans[13] - The net increase in cash and cash equivalents was -$112,074,462.83, contrasting with an increase of $25,893,605.43 in the previous period[33] - The ending balance of cash and cash equivalents was $135,256,618.17, down from $237,288,346.83[33] Assets and Liabilities - The total assets decreased by 8.52% to CNY 1,138.16 million from CNY 1,244.15 million at the end of the previous year[5] - The total liabilities decreased to ¥486,444,440.73 from ¥600,282,029.67, a reduction of about 19.0%[30] - The company’s total assets decreased to CNY 1,138,164,832.76 from CNY 1,244,146,915.63, a decline of about 8.5%[24] - Cash and cash equivalents at the end of the period decreased by 43.00% to ¥135,256,618.17, primarily due to loan repayments[13] Investment Income - The company reported an investment income of CNY 4.35 million, a significant increase of 148.64% from a loss of CNY 8.95 million in the previous year[11] - The company received investment income of ¥8,628,906.69, a substantial increase of 501.78% compared to the previous period[12] - The company reported an investment income of ¥4,353,325.29, a recovery from a loss of ¥8,949,461.99 in the previous period[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,909[14] - The largest shareholder, Deng Guanhua, holds 15.91% of the shares, with a total of 49,194,555 shares pledged[14] Operational Metrics - The weighted average return on equity increased to 1.28%, compared to -0.44% in the previous year[5] - The company’s basic earnings per share improved to CNY 0.03, compared to a loss of CNY 0.01 in the same period last year, marking a 400% increase[5] - The company’s inventory increased slightly to CNY 104,587,534.23 from CNY 102,879,565.59, indicating a growth of about 1.7%[26] - Research and development expenses were ¥6,107,098.10, slightly down from ¥6,602,970.33, indicating a focus on cost management[30] Market and Brand Development - The company launched a functional fibrinogen detection kit (coagulation method) which received a Class II registration certificate, enhancing its diagnostic capabilities in hemostasis[19] - The company was awarded the "2024 Guangzhou Data Governance Demonstration Enterprise" title, recognizing its excellence in data management practices[21] - The company participated in multiple academic and marketing events to enhance its brand image and showcase its technological advancements in veterinary and medical fields[18] - The company is focused on continuous employee training and development to improve operational skills and support organizational goals[22] Other Financial Metrics - The company’s financial expenses decreased by 52.55% to CNY 755,274.58 due to reduced interest expenses and increased foreign exchange gains[11] - The company reported a decrease in other comprehensive income by 95.95% to ¥558.24, indicating a reduction in foreign currency translation differences[12] - The company’s long-term equity investments decreased to CNY 103,282,655.04 from CNY 107,558,236.44, a decrease of approximately 4.3%[26] Accounting Standards - The company’s first quarter report was not audited[34] - The new accounting standards will be implemented starting in 2025[35]

Financial Performance - The company reported a net profit of negative value primarily due to asset impairment, credit impairment, and fair value changes[3]. - The company's operating revenue for 2024 was ¥581,328,009.09, a decrease of 9.82% compared to ¥644,621,152.95 in 2023[21]. - The net profit attributable to shareholders for 2024 was -¥117,903,784.23, representing an 86.55% increase in losses compared to -¥63,203,837.62 in 2023[21]. - The basic earnings per share for 2024 was -¥0.38, a decline of 90.00% from -¥0.2 in 2023[21]. - Total assets at the end of 2024 were ¥1,244,146,915.63, down 12.75% from ¥1,425,956,329.46 at the end of 2023[21]. - The company reported a decrease in net profit excluding non-recurring items to -¥69,977,559.82 in 2024, a 6.10% improvement from -¥74,519,608.96 in 2023[21]. - The company achieved a gross margin of 40.91% in the medical industry, with a decrease of 1.73% compared to the previous year[85]. - Investment income was -8.65 million yuan, a significant decline of 238.75% compared to the previous year's income of 6.24 million yuan[75]. - The company reported a net profit of -¥119,899,161.88 for 2024, worsening from -¥60,220,295.05 in 2023[114]. Operational Strategy - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[4]. - Future plans and performance forecasts mentioned in the report do not constitute a substantive commitment to investors, who should maintain adequate risk awareness[3]. - The company aims to enhance its product advantages by focusing on the top ten technology indicators valued by customers, striving to redefine and reshape customer perceptions[38]. - The company is committed to developing intelligent blood collection management solutions, positioning itself as a preferred service provider for domestic medical institutions[41]. - The company aims to enhance hospital management through digitalization, offering tailored smart hospital solutions and has served over 200 high-level hospitals in Guangdong Province[55]. - Future strategies include continuous technology upgrades, product iterations, and service optimizations to support high-quality hospital management and rapid information system development[56]. - The company is focusing on expanding its market presence and enhancing its product offerings through strategic appointments[167][168]. Market Trends and Industry Insights - The medical device market in China is projected to grow at a compound annual growth rate (CAGR) of 10.2% from 2021 to 2025, reaching ¥1.82 trillion by 2032[30]. - The IVD market in China is projected to reach $6.1 billion in 2024, with an annual growth rate of 8.0%, expected to reach $8.9 billion by 2029[34]. - The global IVD market is expected to grow from $109.2 billion in 2024 to $135.1 billion by 2029, with China’s market share increasing from 6% to 7% during the same period[33]. - The precision medicine industry in China is expected to grow at an annual rate of approximately 12%, with the market size projected to exceed 400 billion yuan by 2028[36]. - The prevalence of cardiovascular diseases (CVD) in China is rising, with an estimated 330 million current cases, highlighting the growing market for the company's thromboelastography products[47]. Product Development and Innovation - The company is actively involved in the formulation and revision of national and industry standards for vacuum blood collection tubes, contributing to industry progress[37]. - The company has developed an integrated solution for smart laboratory management, combining specimen collection systems with intelligent blood collection management and AIM-LIS, focusing on full-process traceability[44]. - The company is currently developing a new type of G6 serum separation gel, which is expected to enhance market competitiveness and increase sales revenue[95]. - The company is developing a low molecular weight heparin product, which is widely used in cardiovascular diseases and dialysis, aiming to enhance product variety and achieve revenue growth[6]. - The company is working on a new technology to create a regional, intelligent medical information system, which will enhance product competitiveness and drive revenue growth[14]. - The company has launched a series of medical devices, including a fully automatic thromboelastography instrument, which is expected to enhance coagulation and anticoagulation analysis capabilities[30]. Risk Management - The company has detailed potential operational risks and corresponding countermeasures in the section discussing future development prospects[3]. - The company faces risks related to industry policy changes, particularly regarding centralized procurement reforms that could impact profit margins despite increased sales[138]. - The company acknowledges risks in new product and technology development, emphasizing the importance of maintaining technological leadership through collaboration and innovation[139]. - The company faces risks from increasing market competition, particularly from multinational companies like Roche and Siemens, which dominate the high-end market[141]. Governance and Compliance - The company emphasizes investor relations and information disclosure, designating the chairman as the primary responsible person for disclosures[152]. - The company has established a comprehensive internal control system to ensure compliance with governance standards[146]. - The board of directors consists of 9 members, including 3 independent directors, ensuring diverse oversight and decision-making[148]. - The company has a strong emphasis on compliance and governance with independent directors possessing extensive expertise in finance and law[169][170]. - The company has not engaged in any significant equity or non-equity investments during the reporting period[123][124]. Human Resources and Training - The total number of employees at the end of the reporting period is 790, with 168 in the parent company and 622 in major subsidiaries[185]. - The professional composition includes 337 technical personnel, 159 production personnel, and 128 sales personnel, indicating a strong focus on technical expertise[185]. - The company has established a comprehensive training system, completing 22 courses that covered all middle management personnel, enhancing their professional and leadership skills[187]. - The training management system has been optimized for timely tracking and precise management of training data, supporting talent assessment and decision-making[188]. Environmental Responsibility - The company has implemented measures to reduce carbon emissions, including upgrading equipment and promoting public transportation for employees[199]. - The company is not classified as a key pollutant discharge unit and has not faced any administrative penalties related to environmental issues during the reporting period[199]. - The company has taken proactive steps to ensure compliance with environmental protection laws and has not experienced any pollution incidents[199].

证券代码：300030 证券简称：阳普医疗 公告编号：2025-024 阳普医疗科技股份有限公司 关于提请股东会授权董事会办理公司 2025 年度 以简易程序向特定对象发行股票相关事宜的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或者重大遗漏。 2.发行方式、发行对象及向原股东配售的安排 本次发行股票采用以简易程序向特定对象发行的方式，发行对象为符合监管 部门规定的法人、自然人或者其他合法投资组织等不超过三十五名的特定对象。 证券投资基金管理公司、证券公司、合格境外机构投资者、人民币合格境外机构 投资者以其管理的二只以上产品认购的，视为一个发行对象。信托公司作为发行 对象的，只能以自有资金认购。最终发行对象将根据申购报价情况，由公司董事 会根据股东会的授权与保荐机构协商确定。本次发行的发行对象均以现金方式认 购。 3.定价基准日，定价原则和发行价格 本次发行的定价基准日为公司本次发行股票的发行期首日。发行价格不低于 定价基准日前 20 个交易日公司 A 股股票均价的 80%（定价基准日前 20 个交易日 A 股股票均价=定价基准日前 20 个交易日 A 股股票交易 ...

Core Insights - The article presents the market capitalization rankings of the top 50 Chinese technology and internet companies as of April 21, 2025, highlighting significant players in the industry [1]. Group 1: Market Capitalization Rankings - JD.com ranks 8th with a market capitalization of $504.58 billion [3]. - SMIC (Semiconductor Manufacturing International Corporation) is in 9th place with a market cap of $473.13 billion [3]. - Kuaishou Technology holds the 10th position with a market cap of $277.81 billion [3]. - Li Auto is ranked 12th with a market capitalization of $247.49 billion [3]. - Tencent Music is in 14th place with a market cap of $210.91 billion [3]. Group 2: Additional Notable Companies - Xpeng Motors is ranked 16th with a market cap of $173.41 billion [3]. - NIO is in 21st place with a market capitalization of $79.71 billion [3]. - Bilibili holds the 23rd position with a market cap of $67.76 billion, showing an upward trend [3]. - Vipshop is ranked 27th with a market cap of $64.15 billion [4]. - Kingsoft has a market cap of $62.85 billion, placing it 28th [4]. Group 3: Market Trends - The rankings reflect the competitive landscape of the Chinese technology sector, with significant fluctuations in market capitalizations among the top companies [1]. - The data is calculated based on the daily market values, converted using the current exchange rate between USD and HKD [5].